Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease

Hyon-Ah Yi1, Christiane Möller2, Nikki Dieleman3

  • 1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea.

Abstract

Insights

Subcortical grey matter atrophy, particularly in the nucleus accumbens and hippocampus, predicts progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Volume loss in these areas also correlates with cognitive impairment severity.

Area of Science:

  • Neuroimaging
  • Neurodegeneration
  • Alzheimer's Disease Research

Background:

  • Subcortical grey matter atrophy is implicated in cognitive decline.
  • Predicting progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is crucial for early intervention.

Purpose of the Study:

  • To determine if subcortical grey matter atrophy predicts MCI to AD progression.
  • To compare subcortical volumes across AD, MCI, and control groups.
  • To assess the relationship between subcortical volumes and cognitive impairment severity.

Main Methods:

  • Utilized 3D T1-weighted MRI scans from 773 participants (181 controls, 201 MCI, 391 AD).
  • Segmented volumes of amygdala, thalamus, caudate nucleus, putamen, globus pallidus, nucleus accumbens, and hippocampus.
  • Followed up participants for 2.0 ± 0.9 years to track MCI to AD conversion.

Main Results:

  • AD patients showed smaller volumes in most subcortical structures compared to controls.
  • MCI patients had smaller amygdala, thalamus, putamen, nucleus accumbens, and hippocampus volumes than controls.
  • Smaller hippocampus and nucleus accumbens volumes were associated with increased risk of MCI to AD progression.
  • Subcortical grey matter volumes correlated positively with cognitive function (MMSE scores).

Conclusions:

  • Nucleus accumbens and hippocampus volume loss are significant predictors of MCI to AD progression.
  • Subcortical grey matter atrophy is linked to the severity of cognitive impairment.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
728
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K